Neurocrine Biosciences Inc. (NASDAQ:NBIX) will unveil its latest earnings on Wednesday, February 8, 2012. Neurocrine Biosciences discovers, develops, and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of one cent per share, a decline of 75% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 20 cents. Between one and three months ago, the average estimate moved down. It has been unchanged at one cent during the last month. For the year, analysts are projecting net income of 66 cents per share, a swing from net loss of 16 cents last year.

Last quarter, the company came in at profit of 56 cents per share against a mean estimate of net income of 9 cents per share, beating estimates after missing them in the previous quarter. In the second quarter, it missed forecasts by 2 cents.

Investing Insights: Will the iPad 3 Be the Next Catalyst for Apple’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $12.1 million in revenue this quarter, a decline of 11.6% from the year ago quarter. Analysts are forecasting total revenue of $78.4 million for the year, a rise of more than twofold from last year’s revenue of $33.5 million.

Analyst Ratings: Analysts are bullish on this stock with seven analysts rating it as a buy, none rating it as a sell and two rating it as a hold.

A Look Back: In the third quarter, profit rose 841.6% to $31.4 million (56 cents a share) from $3.3 million (6 cents a share) the year earlier, exceeding analyst expectations. Revenue rose more than twofold to $41.6 million from $14.4 million.

Stock Price Performance: During December 5, 2011 to February 2, 2012, the stock price had risen $2.79 (39.9%) from $7 to $9.79. The stock price saw one of its best stretches over the last year between November 29, 2011 and December 16, 2011 when shares rose for 14-straight days, rising 27.3% (+$1.69) over that span. It saw one of its worst periods between July 7, 2011 and July 19, 2011 when shares fell for nine-straight days, falling 7% (-59 cents) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

These Retailers Continue to Confuse Investors

Are You Ready for Some Super Bowl Inflation?

Is 2012 the Year of the Golden Dragon?

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com

Get Your FREE Special Report: 4 Things You Must Know About the US Economy Now!